Thyroid medication (under and over active) and Breastfeeding

The information provided is taken from various reference sources. It is provided as a guideline. No responsibility can be taken by the author or the Breastfeeding Network for the way in which the information is used. Clinical decisions remain the responsibility of medical and breastfeeding practitioners. The data presented here is intended to provide some immediate information but cannot replace input from professionals.

Under-active thyroid
A mother with an under active thyroid needs to take medication to return her blood levels to "normal". The dose of the drug is regulated by therapeutic drug monitoring. It is worth repeating blood levels after delivery as anecdotally, fluctuations seem common at this time. If the supplementation is too low, prolactin levels will be affected resulting in a poor milk supply. The correct dose gives a mother the level of levothyroxine of a normal breastfeeding mother. Symptoms of an under active thyroid include gain in body weight, dry skin and hair and tiredness.

Levothyroxine is secreted in extremely low levels into breastmilk, if at all. It is highly bound to proteins in the maternal plasma. The estimated level to which the baby will be exposed is theoretically 0.6 nanogrammes per kilogramme per day - virtually undetectable. Levels secreted into milk are too low to influence tests for neonatal hypothyroidism.

Over-active thyroid
A mother with an over active thyroid gland produces raised levels of levothyroxine and will experience symptoms which may include tachycardia (increased heart rate), sweating, heat intolerance and loss of body weight. Symptoms are initially controlled by anti-thyroid drugs (carbimazole or propylthiouracil) and beta blockers. In some cases the gland is removed surgically or by the use of radioactive iodine and levels replaced by synthetic levothyroxine.

Carbimazole (Neomercazole*) reaches sub-clinical levels in infants exposed to less than 30milligrammes a day through their mother’s breastmilk. The theoretical infant dose is 6.45 microgrammes per kg per day. If this drug is used monitoring of the infant’s thyroid function is recommended but not always essential.

Propylthiouracil (PTU) is the drug of choice in a breastfeeding mother. Only small amounts are secreted into breastmilk and reports suggest that levels are too low to produce side effects. At doses of 400milligrammes, a study of 9 women and their babies showed no change in infant thyroid function (Kampmann 1980). A further study has shown that up to 750milligrammes produces no changes (Momotani 2000. However monitoring is recommended but not always essential. Theoretical infant dose is quoted as 0.105milligrammes/kg/day (Hale 2014)

Bibliography
To speak to a Breastfeeding Supporter call the National Breastfeeding Helpline 0300 100 0212

Calls to 0300 numbers cost no more than calls to UK numbers starting 01 and 02 and will be part of any inclusive minutes that apply to your provider and call package.

The Breastfeeding Network is a Company Limited by Guarantee Registered in Scotland Company No. 330639
Registered office Whitelaw Wells, 9 Ainslie Place, Edinburgh, EH3 6AT
The Breastfeeding Network is a Registered Scottish Charity No SC027007
©Wendy Jones PhD, MRPharmS and the Breastfeeding Network May 2017
To find your nearest Breastfeeding Supporter call the **Supporterline 0300 100 0210**

- British National Formulary
- Hale T. Medications in Mothers Milk 2014(16th Ed)
- Jones W Breastfeeding and Medication 2013 Routledge

To speak to a Breastfeeding Supporter call the **National Breastfeeding Helpline 0300 100 0212**

Calls to 0300 numbers cost no more than calls to UK numbers starting 01 and 02 and will be part of any inclusive minutes that apply to your provider and call package

The Breastfeeding Network is a Company Limited by Guarantee Registered in Scotland Company No. 330639
Registered office Whitelaw Wells, 9 Ainslie Place, Edinburgh, EH3 6AT
The Breastfeeding Network is a Registered Scottish Charity No SC027007

©Wendy Jones PhD, MRPharmS and the Breastfeeding Network May 2017